Bristol Myers: positive long-term data for Zeposia

(CercleFinance.com) - Bristol Myers Squibb reports new long-term data from the DAYBREAK Phase III trial of its Zeposia product, demonstrating sustained efficacy and consistent safety in relapsing forms of multiple sclerosis.


The pharmaceutical company reports that brain volume loss decreased over the course of the Phase III studies, and was maintained by treatment with Zeposia for up to five years.

More than eight years of data from the DAYBREAK study confirm Zeposia's established safety profile, with treatment-related adverse event rates declining or stable over time, Bristol Myers adds.


Copyright (c) 2024 CercleFinance.com. All rights reserved.